{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:34:42Z","timestamp":1787236482412,"version":"build-2736575974"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.acvd.2023.11.010","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:32:09Z","timestamp":1700760729000},"page":"29-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anticoagulant treatment of cancer-associated thromboembolism"],"prefix":"10.1016","volume":"117","author":[{"given":"Isabelle","family":"Mah\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Mayeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Couturaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ygal","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmahane","family":"Benmaziane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-3010","authenticated-orcid":false,"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-8668","authenticated-orcid":false,"given":"Silvy","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-8055","authenticated-orcid":false,"given":"Philippe","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-8391","authenticated-orcid":false,"given":"Olivier","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2023.11.010_bib0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.acvd.2023.11.010_bib0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.107.726232","article-title":"Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry","volume":"117","author":"Laporte","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2023.11.010_bib0020","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.acvd.2023.11.010_bib0025","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.acvd.2023.11.010_bib0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0040","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0045","first-page":"1181","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.acvd.2023.11.010_bib0050","first-page":"101056","article-title":"French guidelines for the treatment of cancer-associated venous thromboembolism\u00a0\u2013\u00a02023 update","volume":"84","author":"Mah\u00e9","year":"2023","journal-title":"Respir Med Res"},{"key":"10.1016\/j.acvd.2023.11.010_bib0055","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0060","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2023.11.010_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2023.11.005","article-title":"Care pathways for patients with cancer associated thrombosis: from diagnosis to long-term follow-up","volume":"117","author":"Sevestre","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2023.11.010_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2023.11.009","article-title":"Management of cancer-associated thromboembolism in vulnerable population","volume":"117","author":"Laporte","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2023.11.010_bib0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/cancers11010048","article-title":"Treatment and prevention of cancer-associated thrombosis in frail patients: tailored management","volume":"11","author":"Scotte","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acvd.2023.11.010_bib0080","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2023.11.010_bib0085","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/jth.15435","article-title":"Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"19","author":"Caiano","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0090","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02723-2020","article-title":"Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism","volume":"58","author":"Peris","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.acvd.2023.11.010_bib0095","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/bloodadvances.2020001501","article-title":"Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients","volume":"4","author":"Qdaisat","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.acvd.2023.11.010_bib0100","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"McBane","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0110","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/jth.15214","article-title":"Clinical history of cancer-associated splanchnic vein thrombosis","volume":"19","author":"Valeriani","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0115","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1182\/bloodadvances.2022007961","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis","volume":"6","author":"Candeloro","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.acvd.2023.11.010_bib0120","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/jth.15416","article-title":"Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis","volume":"19","author":"Vlazny","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2023.05.027","article-title":"Incidence of recurrent venous thromboembolism and bleeding complications in patients with cancer and isolated distal deep vein thrombosis","volume":"228","author":"Brown","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2023.11.010_bib0130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.010_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2023.11.012","article-title":"Home treatment for patients with cancer-associated venous thrombo-embolism","volume":"117","author":"Sanchez","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2023.11.010_bib0140","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.0000137826.09715.9C","article-title":"Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials","volume":"110","author":"Wan","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2023.11.010_bib0145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs. dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2023.11.010_bib0150","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0155","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio Study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"Suppl2","key":"10.1016\/j.acvd.2023.11.010_bib0170","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1182\/blood-2023-177979","article-title":"Efficacy and safety outcomes in patients with cancer-associated thromboembolism treated with tinzaparin according to the tumor site: meta-analysis of prospective studies involving 1413 individual patients\u2019 data","volume":"142","author":"Mah\u00e9","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.acvd.2023.11.010_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2023.11.004","article-title":"Management of venous thromboembolic disease in patients with malignant brain","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2023.11.010_bib0180","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/annonc\/mdy035","article-title":"Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events\u00a0\u2013\u00a0a meta-analysis","volume":"29","author":"Trone","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0185","first-page":"19","article-title":"The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects","volume":"9","author":"Frost","year":"2017","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0190","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/pharmaceutics12090846","article-title":"Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice","volume":"12","author":"Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.acvd.2023.11.010_bib0195","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2014.07.967","article-title":"Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"64","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0200","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acvd.2023.11.010_bib0205","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00228-023-03501-8","article-title":"Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database","volume":"79","author":"Gosselin","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0210","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/M22-3238","article-title":"Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: a retrospective cohort study","volume":"176","author":"Ray","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0215","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/pds.4896","article-title":"Poor concordance among drug compendia for proposed interactions between enzyme-inducing antiepileptic drugs and direct oral anticoagulants","volume":"28","author":"Acton","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2023.11.010_bib0220","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2023.11.010_bib0225","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.010_bib0230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.06.015","article-title":"Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: clinical consequences","volume":"129","author":"Bellesoeur","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0235","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620936325","article-title":"Drug\u2013drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms","volume":"26","author":"Peixoto de Miranda","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0240","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug\u2013drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.acvd.2023.11.010_bib0245","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15785","article-title":"Pharmacokinetic drug\u2013drug interactions with direct anticoagulants in the management of cancer-associated thrombosis","author":"Van der Linden","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0250","doi-asserted-by":"crossref","first-page":"e00647","DOI":"10.1002\/prp2.647","article-title":"Drug interactions with apixaban: a systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports","volume":"8","author":"Fernandez","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.acvd.2023.11.010_bib0255","series-title":"Th\u00e9saurus des int\u00e9ractions m\u00e9dicamenteusess","year":"2023"},{"key":"10.1016\/j.acvd.2023.11.010_bib0260","series-title":"BNF: British National Formulary","year":"2023"},{"key":"10.1016\/j.acvd.2023.11.010_bib0265","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.acvd.2023.11.010_bib0270","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/0269216318757133","article-title":"Cancer patients\u2019 experiences of living with venous thromboembolism: a systematic review and qualitative thematic synthesis","volume":"32","author":"Benelhaj","year":"2018","journal-title":"Palliat Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2021.06.021","article-title":"Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism\u00a0\u2013\u00a0The COSIMO study","volume":"206","author":"Cohen","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2023.11.010_bib0280","first-page":"LPB0041","article-title":"Improved Patient-reported treatment satisfaction with rivaroxaban as compared to low molecular weight heparins for cancer patients with acute venous thromboembolism\u00a0\u2013\u00a0Results from the CONKO-011 Trial","volume":"5","author":"Riess","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0285","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0269216318815377","article-title":"Oral anticoagulation is preferable to injected, but only if it is safe and effective: an interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial","volume":"33","author":"Hutchinson","year":"2019","journal-title":"Palliat Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0295","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"Schaefer","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0300","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0305","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0310","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs. low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2023.11.010_bib0315","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0320","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"Ageno","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0325","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2020.02.005","article-title":"Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism","volume":"188","author":"Schmidt","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2023.11.010_bib0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082256","article-title":"Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study","volume":"12","author":"Mah\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acvd.2023.11.010_bib0335","doi-asserted-by":"crossref","first-page":"347","DOI":"10.26502\/jcsct.5079122","article-title":"Reasons influencing long-term anticoagulant treatment beyond 6 months for cancer-associated thrombosis in USCAT, a 432-patient retrospective non-interventional study","volume":"5","author":"Plaisance","year":"2021","journal-title":"J Cancer Sci Clin Ther"},{"key":"10.1016\/j.acvd.2023.11.010_bib0340","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15113011","article-title":"Low molecular weight heparin treatment patterns and outcomes in cancer patients with acute venous thromboembolism: a nationwide cohort study in France","volume":"15","author":"Bertoletti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acvd.2023.11.010_bib0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"Cohen","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0350","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis-rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"Moik","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0355","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2013.51.7433","article-title":"Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study","volume":"32","author":"Napolitano","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2023.11.010_bib0360","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0365","first-page":"102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama Vlieg","year":"2023","journal-title":"eClin Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0370","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0375","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"Chee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.acvd.2023.11.010_bib0380","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.acvd.2023.11.010_bib0385","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.chest.2015.10.069","article-title":"Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer","volume":"149","author":"van der Hulle","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2023.11.010_bib0390","doi-asserted-by":"crossref","first-page":"100115","DOI":"10.1016\/j.rpth.2023.100115","article-title":"Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy","volume":"7","author":"Barca-Hernando","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0395","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jtha.2023.04.010","article-title":"Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study","volume":"21","author":"Lap\u00e9bie","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0400","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0405","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.acvd.2023.11.010_bib0410","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.rpth.2023.100293","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients","volume":"7","author":"McBane","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0415","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients\u00a0\u2013\u00a030 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0420","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT Study","volume":"122","author":"Mah\u00e9","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.010_bib0425","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2023.11.010_bib0430","doi-asserted-by":"crossref","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2023.11.010_bib0435","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01647-2019","volume":"54","author":"Konstantinides","year":"2019","journal-title":"Eur Respir J"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213623005193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213623005193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:50:07Z","timestamp":1761745807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213623005193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1875213623005193"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2023.11.010","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant treatment of cancer-associated thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2023.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}